Conference Description:

This December, the 4th Annual Gene Therapy for Neurological Disorders meeting is returning to Boston to welcome discovery, preclinical, translational and clinical industry scientists to share, learn and network for the shared goal of successfully and safely delivering gene therapies to the CNS.

Join the expanding audience of gene therapy experts seeking to overcome the translational hurdles of developing gene therapies for CNS targets, from discovery, preclinical, translational, clinical, and commercial departments at the likes of Capsigen, AviadoBio, AskBio,Novartis, Prevail Therapeutics,Passage Bio,Voyager Therapeutics,UniQure and more.

Group discounts and early booking rates are available. Please visit the website for full pricing information.

Tickets: https://go.evvnt.com/1285927-3?pid=154
Prices:
Industry Rate - FULL ACCESS PASS: Conference + Workshop Day AND Post Conference Vector Day: USD 4893.00,
Industry Rate - Conference + Workshop Day Or Post Conference Vector Day: USD 3996.00,
Industry Rate - Conference Only: USD 3099.00,
Academic Rate - FULL ACCESS PASS: Conference + Workshop Day AND Post Conference Vector Day: USD 3893.00,
Academic Rate - Conference + Workshop Day Or Post Conference Vector Day: USD 3296.00,
Academic Rate - Conference Only: USD 2699.00

Speakers: Anna Kajaste-Rudnitski, Group Leader, San Raffaele Hospital, David Huss, Chief Scientific Officer, Shape Therapeutics, Jacinthe Gingras, Senior Director - Ophthalmology and Neurology, Homology Medicines, Kennon Smith, Lead Scientist - Platform, Stridebio, Allie Stanton, Phd Candidate - Pardis Sabeti Lab, Harvard Medical School, Maria Praggastis, Staff Scientist Regeneron, Pharmaceuticals, Sharyl Fyffe-Maricich, Executive Director - Molecular and Cellular Biology Research, Ultragenyx, Shyam Ramachandran, Neuroscience Head - Genomic Medicine Unit, Sanofi, Anindya Sen, Director - Pre-Clinical Research and Development, Prevail Therapeutics, Edgar Rodriguez, Chief Executive Officer and Co-Founder, Lacerta Therapeutics, Samir Koirala, Director, Biogen, Zhenpeng Qin, Associate Professor of Mechanical Engineering, University of Texas at Dallas, Boaz Levi, Associate Investigator - Human Cell Types, Allen Institute, Martin Ingelsson, Professor and Clinician Scientist, Tanz Centre for Research In Neurodegenerative Diseases, University of Toronto, Rodolphe Clerval, Chief Executive Officer, Coave Therapeutics, Steven Cohen, Executive Director, Daiichi Sankyo, Elizabeth Ramsburg, Head Of Central Nervous System and Research, Spark Therapeutics, Jay Barth, Chief Medical Officer, Lexeo Therapeutics, Lingzhi Zhao, Senior Director - Gene Therapy and Transnational Discovery, AGTC, Ruby Boyanapalli, Associate Director, Takeda, Benjamin Shykind, Senior Director - Discovery, Prevail Therapeutics, Eric Schaeffer, Chief Scientific Officer, Paros Bio, Heather Lau, Executive Director, Ultragenyx Pharmaceutical, Roger Chung, Chief Scientific Officer, Celosia Therapeutics, Amber Van Laar, Vice President, Clinical Development, AskBio, Brittany Hernandez, Executive Vice President, Crossroad Strategies, Bryn Martin, Vice President, Research, Precision Delivery, and CSF Sciences, Alcyone Therapeutics, Inc, Jennifer Johnston, Cofounder and Chief Executive Officer, NysnoBio, Kristin Stephenson, Director - Strategy and Alliances, St. Jude Children's Research Hospital, Laura Jane Smith, Principle Scientist and Scientific Co-founder, Homology Medicines, Mark Tuszynski, Professor, University of California, School of Medicine, Ken Mullinix, Head of Surgical Services, Biomere, Peter Pechan, Head of Vector Biology, GTVC, UCB Boston, Serene Forte, Senior Vice President, Head of Genetic Medicine, Relief Therapeutics, Amy Brin, Executive Director and CEO, The Child Neurology Foundation, Ben Deverman, Director of Vector Engineering, Stanley Center for Psychiatric Research, Broad Institute, Thomas Packard, Associate Director, Shape Therapeutics

Time: 08:00 to 14:30